(Q43713527)

26 November 2017

In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel (English)

1 reference

26 November 2017

0 references

1 reference

3

1 reference

26 November 2017

Liang YS

1

1 reference

PubMed ID

11513892

26 November 2017

Coles GC

series ordinal

2

1 reference

PubMed ID

11513892

26 November 2017

Southgate VR

series ordinal

4

1 reference

26 November 2017

1 September 2001

1 reference

International Journal for Parasitology

26 November 2017

1 reference

26 November 2017

31

1 reference

26 November 2017

11

1 reference

26 November 2017

1227-1235

1 reference

Praziquantel: mechanisms of anti-schistosomal activity

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

The relationship between tegumental disruption and muscle contraction in Schistosoma mansoni exposed to various compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Hycanthone resistance in a human strain of Schistosoma mansoni.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

The effect of Praziquantel on Schistosoma mansoni

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Defining resistance in Schistosoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Tolerance of Kenyan Schistosoma mansoni to oxamniquine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Experimental chemotherapy of Schistosoma mansoni with praziquantel and oxamniquine: differential effect of single or combined formulations of drugs on various strains and on both sexes of the parasite

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Efficacy of treatment of murine Schistosoma mansoni infections with praziquantel and oxamniquine correlates with infection intensity: role of host antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Praziquantel, a new broad-spectrum antischistosomal agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Detection of praziquantel resistance in schistosomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

A perfusion procedure (perf-o-suction) for recovery of schistosome worms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Effect of praziquantel on larval stages of Schistosoma japonicum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2801%2900246-6

10.1016/S0020-7519(01)00246-6

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference

PubMed ID

11513892